France With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination for international investments, France is looking to boost innovation, attracting the largest number of R&D centres in Europe in 2022,…
France France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has demonstrated its willingness to take steps towards levelling its pricing barometers and in so doing tackle medicine shortages and build…
France Philippe Lamoureux, director of LEEM, the pharmaceutical industry’s association in France, reflects on the winds of change in the sector after the establishment of the Macron government, the 2018 Strategic Council of Health Industries (CSIS) and new pro-industry measures. I believe that we can make France a worldwide leader in…
LEEM - Les Enterprises du Medicament What are the main tasks of the LEEM? The LEEM is the only professional organization representing the pharmaceutical industry in France. It includes almost all companies which seek to develop, manufacture and market drugs. Leem represents all components of the profession: international groups, medium-sized companies, an important fabric of small,…
LEEM - Les Enterprises du Medicament Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes in the French pharmaceutical market and to what extent has France kept up? I think France has kept up with the world market albeit with some notable differences, namely in terms of our…
See our Cookie Privacy Policy Here